Date:	8/31/22	
Your Name:	Nathan Arboleda	
Manuscript Title: A Revie	ew Ocular Surface Disease Consideration	s in the Management of Glaucoma
Manuscript number (if I	known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third

parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u>

manuscript only.

The author's relationships/activities/interests should be <u>defined</u> <u>broadly</u>. For example, if your manuscript pertains

to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,

the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	x_None	

3	Royalties or licenses	x_None	
4	Consulting fees	x_None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	x_None	
6	Payment for expert testimony	xNone	
7	Support for attending meetings and/or travel	x_None	
8	Patents planned, issued or pending	x_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	x_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	x_None	
11	Stock or stock options	xNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	x_None	
13	Other financial or non- financial interests	x_None	

Please summarize the above conflict of interest in the following box:

No COIs			

Please place an "X" next to the following statement to indicate your agreement:
_x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	09/01/2022				
Manu	Your Name: <u>Wen-Jeng (Melissa) Yao</u> Manuscript Title: A Review of Ocular Surface Disease Considerations in the Management of Glaucoma Manuscript number (if known):				
that a	re	ed" means any relation with for-profit or not-for-profit			
partie comn to tra	carties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.				
curre	The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.				
The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.					
other	n #1 below, report all support for the work items, ne frame for disclosure is the past 36 mont	reported in this manuscript without time limit. For all			
	Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your			

Time frame: Since the initial planning of the wo  1 All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	/Comments nts were made to you or to your
present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	work
No time limit for this item.	

2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone
3	Royalties or licenses	x_None
4	Consulting fees	x_None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_xNone
6	Payment for expert testimony	_xNone
7	Support for attending meetings and/or travel	_xNone
8	Patents planned, issued or pending	xNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	x_None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_xNone
11	Stock or stock options	x_None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_xNone
13	Other financial or non- financial interests	xNone
Ple	ease summarize the abo	ve conflict of interest in the following box:

Please place an "X" next to the following statement to indicate your agreement:		
_x I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date: 09/0	7/2022			
		ase Considerations in the Management of Glauc	<u>:oma</u> —	
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third				
commitment	not necessarily indicate	ntent of the manuscript. Disclosure represents a a bias. If you are in doubt about whether to list ou do so.		
The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.				
The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.  In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.				
	·			
	Name all entities with whom you have this relationship or indicate none (add rows as needed) ime frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)		

		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)	
	Ti	me frame: Since the initia	I planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	x_None		
	Time frame: past 36 months			
2	Grants or contracts from	x_None		

	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	xNone	
	Troyantioo or moonlood		
4	Consulting fees	x_None	
_	D		
5	Payment or honoraria for lectures, presentations,	_xNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_xNone	
	testimony		
7	Support for attending	x None	
<b>'</b>	meetings and/or travel	_xNone	
	J		
8	Patents planned, issued	x_None	
	or pending		
0	Double in ation on a Date	v Name	
9	Participation on a Data Safety Monitoring Board	x_None	
	or Advisory Board		
10	10 Leadership or fiduciary role in other board,	_xNone	
	society, committee or		
	advocacy group, paid or		
11	unpaid Stock or stock options	x None	
	Otook of Stook options		
12	Receipt of equipment,	_xNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	xNone	
	financial interests		
Ple	ease summarize the abo	ve conflict of interest i	the following box:
			This is is in a series of the

Please place an "X" next to the following statement to indicate your agreement:
_x I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	09/02/2022
	Gene Kim itle: <u>A Review of Ocular Surface Disease Considerations in the Management of Glaucom</u> umber (if known):
In the interes	t of transparency, we ask you to disclose all relationships/activities/interests listed below
	content of your manuscript. "Related" means any relation with for-profit or not-for-profi
	e interests may be affected by the content of the manuscript. Disclosure represents a
to transparer	cy and does not necessarily indicate a bias. If you are in doubt about whether to list a activity/interest, it is preferable that you do so.
The following current manuscript c	questions apply to the author's relationships/activities/interests as they relate to the <u>nly</u> .
pertains to the epiden	relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscriology of hypertension, you should declare all relationships with manufacturers of sive medication, even if that medication is not mentioned in the manuscript.
In item #1 be other items,	ow, report all support for the work reported in this manuscript without time limit. For all e for disclosure is the past 36 months.
	None all audition with Constitution (Constitution)
	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial planning of the work

		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)				
	Time frame: Since the initial planning of the work						
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_x_None					
	110111.	— ·					
		Time frame: past	36 months				
2	Grants or contracts from	xNone					

	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	xNone	
	Troyantioo or moonlood		
4	Consulting fees	x_None	
_	D		
5	Payment or honoraria for lectures, presentations, speakers bureaus,	_xNone	
	manuscript writing or		
	educational events		
6	Payment for expert	_xNone	
	testimony		
7	Support for attending	x None	
<b>'</b>	meetings and/or travel	_xNone	
	J		
8	Patents planned, issued	x_None	
	or pending		
0	Double in ation on a Date	v Name	
9	Participation on a Data Safety Monitoring Board	x_None	
	or Advisory Board		
10	Leadership or fiduciary	_xNone	
	role in other board, society, committee or advocacy group, paid or		
11	unpaid Stock or stock options	x None	
	Otook of Stook options		
12	Receipt of equipment,	_xNone	
	materials, drugs, medical		
	writing, gifts or other		
13	Other financial or non-financial interests	xNone	
'			
Ple	ease summarize the abo	ve conflict of interest i	the following box:
			This is is in a series of the

Please place an "X" next to the following statement to indicate your agreement:
_x I certify that I have answered every question and have not altered the wording of any of the questions on this form.